Western blot analysis of extracts from BxPc-3 cells treated with EGF (100 ng/ml for 5 min) or EGF plus the EGF receptor tyrosine kinase inhibitor Gefitinib (10 uM for 2 hrs), using Phospho-EGF Receptor (Tyr1173) (53A5) Rabbit mAb (upper) or EGF Receptor Antibody #2232 (lower).
Phospho-EGF Receptor (Tyr1173) (53A5) Rabbit mAb specifically binds to tyrosine phosphorylated EGF receptors but not other phosphorylated tyrosine kinases. Western blot analysis of extracts from cells expressing different activated tyrosine kinase proteins, using Phospho-EGF Receptor (Tyr1173)(53A5) Rabbit mAb (upper) or Phospho-Tyrosine mAb (P-Tyr-100) #9411 (lower).
Immunohistochemical analysis of paraffin-embedded human breast carcinoma, using Phospho-EGF Receptor (Tyr1173) (53A5) Rabbit mAb.
Immunohistochemical analysis of paraffin-embedded human breast carcinoma, untreated (left) or calf-intestinal phosphatase (CIP) treated (right), using Phospho-EGF Receptor (Tyr1173) (53A5) Rabbit mAb.
Immunohistochemical analysis using Phospho-EGF Receptor (Tyr1173) (53A5) Rabbit mAb on SignalSlide™ Phospho-EGF Receptor IHC Controls #8102 (paraffin-embedded KYSE450 cell pellets, untreated (left) or EGF-treated (right)).
Immunohistochemical analysis of paraffin-embedded human prostate carcinoma, using Phospho-EGF Receptor (Tyr1173)(53A5) Rabbit mAb (left) or the same antibody preincubated with Phospho-EGF Receptor (Tyr1173) Blocking Peptide (#1175) (right).